Inhibikase Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview

Inhibikase Therapeutics

08/08/2023 12:33

* Inhibikase Therapeutics Inc  IKT.OQ   IKT.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
15. 
    * 
    * ​Refinitiv's mean analyst estimate for Inhibikase
Therapeutics
Inc is for a loss of 92 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $27​, above​ its last closing price
of $2.39. ​​​

This summary was machine generated August 8 at 11:33 GMT.  All
figures in US dollars  unless otherwise stated